- Four pharmaceutical companies involved in the first U.S. negotiations over prices for the Medicare program said they do not expect a significant impact on their businesses after seeing confidential suggested prices from the government for their drugs that will take effect in 2026.
Bristol Myers CEO Chris Boerner on Friday said the company was increasingly confident it could navigate the IRA's impact on the blockbuster blood thinner Eliquis it shares with Pfizer, having seen the government price. Several drugmakers as well as industry lobbying groups PhRMA and the U.S. Chamber of Commerce filed lawsuits to stop the prices from going into effect, which have largely failed.“As expected, price setting has been a flawed and political process," said Nicole Longo, spokeswoman for PhRMA.
J&J executive Jennifer Taubert said the company's long-term growth forecast "still looks very good to us today," after seeing the discounts suggested by the government for its top-selling psoriasis drug Stelara and blood thinner Xarelto, which are among the first 10 chosen for negotiations.
مصر أحدث الأخبار, مصر عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
مصدر: YahooFinanceCA - 🏆 47. / 63 اقرأ أكثر »